Dengvaxia Market 2026–2035 expanding with dengue prevention initiatives

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Dengvaxia Market Expected To Change Between 2026 And 2030?

The dengvaxia market has seen significant expansion in recent years. Its valuation is anticipated to climb from $213.36 million in 2025 to $250.81 million in 2026, achieving a compound annual growth rate (CAGR) of 17.6%. The impetus for this historical growth includes ongoing dengue outbreaks, a considerable disease burden within tropical regions, government-spearheaded immunization drives, restricted treatment options for dengue, and growing awareness regarding public health.

The dengvaxia market size is anticipated to experience substantial growth in the coming years. It is projected to reach $473.95 million by 2030, demonstrating a compound annual growth rate (CAGR) of 17.2%. This expansion during the forecast period is attributed to factors like the broadening of vaccination coverage, increasing climate-driven mosquito spread, a rise in public health funding, improved vaccine delivery infrastructure, and growing demand for travel-related immunization. Key trends expected over this period include the expansion of dengue vaccination programs, a heightened focus on preventing endemic diseases, an increase in public health immunization campaigns, enhanced surveillance of mosquito-borne diseases, and strengthened pediatric and adolescent vaccination efforts.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20035&type=smp

Which Major Factors Are Driving The Expansion Of The Dengvaxia Market?

The high prevalence of dengue is anticipated to stimulate the growth of the dengvaxia market moving forward. Dengue, a viral infection transmitted by Aedes mosquitoes, manifests with flu-like symptoms, intense pain, and, in severe instances, potentially fatal complications such as dengue hemorrhagic fever or dengue shock syndrome. The increasing occurrence of dengue stems from factors like climate change, urbanization, greater travel, and expanding mosquito breeding grounds, contributing to elevated infection rates and a higher demand for preventative and curative measures. Dengvaxia aids in dengue prevention as it is an effective vaccine that prompts the immune system to mount a protective response against the dengue virus, thereby mitigating the risk of infection and severe complications and fostering improved public health outcomes in endemic regions. For example, in June 2024, data from the Centers for Disease Control and Prevention (CDC), a US-based government agency, indicated that the Americas recorded over 9.7 million dengue cases, which is double the 4.6 million cases reported in 2023. Furthermore, Puerto Rico declared a public health emergency with 1,498 cases, and 745 cases were documented among U.S. travelers. Consequently, the significant incidence of dengue is propelling expansion in the dengvaxia market.

Dengvaxia Market Driver: Impact Of Rising International Travel On Market Growth

How Is The Dengvaxia Market Structured Across Different Segments?

The dengvaxia market covered in this report is segmented –

1) By Type: Dengvaxia, Other Types

2) By Distribution Channel: Hospitals, Clinics, Public Health Programs

3) By Clinical Indication: Prevention In Previously Infected Individuals, Protection In High-Risk Regions, Traveler Immunization, Pediatric And Adolescent Use

Which Major Players Dominate The Dengvaxia Market?

Major companies operating in the dengvaxia market are Sanofi Pasteur Inc.

Read the full dengvaxia market report here:

https://www.thebusinessresearchcompany.com/report/dengvaxia-global-market-report

Which Region Currently Holds The Largest Share Of The Dengvaxia Market?

Asia-Pacific was the largest region in the dengvaxia market in 2025. Latin America is expected to be the fastest-growing region in the forecast period. The regions covered in the dengvaxia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Dengvaxia Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20035&type=smp

Browse Through More Reports Similar to the Global Dengvaxia Market 2026, By The Business Research Company

Rare Neurological Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-neurological-disease-treatment-global-market-report

Vaccine Contract Manufacturing Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccine-contract-manufacturing-global-market-report

Malaria Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/malaria-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795